CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell...
Phase 2
Villejuif, France and 47 other locations
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell...
Phase 2
Paris, France and 83 other locations
in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with o...
Phase 3
Paris, France and 205 other locations
type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...
Phase 1, Phase 2
Paris, France and 123 other locations
This is a phase 3 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) compared to pembrolizumab in front-line, PD-L1-high, loca...
Phase 3
Boulogne-Billancourt, France and 170 other locations
in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer...
Phase 3
Paris, France and 139 other locations
over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non...
Phase 1
Villejuif Cedex, France and 36 other locations
PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC)....
Phase 2
Paris, France and 126 other locations
A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung...
Phase 2
Creteil, France and 137 other locations
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...
Phase 2
Paris, France and 122 other locations
Clinical trials
Research sites
Resources
Legal